ResMed Inc. (RMD) Fair Value 2026

RMD · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.4 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-08-27, ResMed Inc. (RMD) trades at $235.76, versus a $217.59 median fair value across its 11 active models — 7.7% below the current price. QOC: 9.4/10. Value Trap Risk: 12/100 (SAFE). 11/13 models active. Within that set, the Bayesian DCF component alone returns $303.45.

Key Facts

Ticker
RMD
Price
$235.76
Quality Score
9.4/10
Value Trap Risk
12/100
Models Active
11/13
Last Updated
Strength: Bayesian DCF suggests +28.7% upside with 79% confidence
Risk: Limited model coverage (11/13) may reduce confidence

Is ResMed Inc. (RMD) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, ResMed Inc. (RMD) appears fairly valued as of : the median of 11 independent fair value estimates is $217.59, within 7.7% of the current price of $235.76. Estimates range from $97.59 to $487.64. RMD scores 9.4/10 on fundamental quality and 12/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. RMD’s -7.7% gap is narrower than that market norm, and the Medical Instruments & Supplies sector median is -36.1%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy ResMed Inc. Stock in 2026? →

What Fair Value Does Each Model Give RMD?

11 Intrinsic Value Models vs. Current Price ($235.76)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $303.45 +28.7%
Intrinsic · High Conviction
 $125.18 -46.9%
Ensemble · Medium Conviction
 $212.75 -9.8%
Scenario · High Conviction
 $284.13 +20.5%
Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is RMD's Fair Value Range?

Spread across 11 independent models · $97.59 to $487.64

CirclFi's 11 active models place ResMed Inc. (RMD) between $97.59 and $487.64 per share, a spread of 179% of the median. The median of that range — $217.59 — is the fair value CirclFi publishes for RMD, against a current price of $235.76.

Low · EROICHigh · Regime Cross
$97.59median $217.59$487.64
Where the range comes from
Most bearish modelEROIC Spread$97.59
Most bullish modelRegime Cross-Sectional$487.64
Model agreement4 bullish · 6 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for RMD. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on RMD, not a CirclFi price target. How each model works →

What Is ResMed Inc. (RMD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, ResMed Inc. presents a highly debated valuation profile at its current price of $235.76. The median intrinsic value is estimated at $217.59 (-7.7% median upside), masking a wide model spread between the 4 bullish models and 6 bearish models. Model dispersion is worth noting: Regime Cross targets $487.64 (+106.8%), versus EROIC at $97.59 (-58.6%). This +165.4% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Bayesian DCF, EPV, EROIC lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About RMD?

11 of 13 models are currently active for RMD. Of these, 4 models suggest upside while 7 models suggest overvaluation. Taken together, their median fair value for RMD is $217.59 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $303.45 on its own, implying +28.7% upside from the current price. See which stocks rank higher →

How Does RMD Rank in Medical Instruments & Supplies?

Among 55 Medical Instruments & Supplies stocks, RMD ranks #2 by Quality of Company score. CirclFi's QOC score of 9.4/10 evaluates 32 fundamental signals. A score of 9.4 places RMD in the top tier.

See all Most Undervalued Medical Instruments & Supplies Stocks →

ResMed Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is RMD a Value Trap?

CirclFi's Value Trap algorithm assigns RMD a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for ResMed Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, ResMed Inc. is rated at 9.4/10. This elite-tier score ranks among the highest-quality businesses in our coverage universe.

The gap between the most bullish and bearish model spans +165.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RMD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across RMD's 11 active models, average confidence is 61%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy ResMed Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

9 related Medical Instruments & Supplies stocks with 13-model coverage

ISRGIntuitive Surgical, Inc.QOC 9.4LMATLeMaitre Vascular, Inc.QOC 9.3NNNNAnbio BiotechnologyQOC 2.4ATRAptarGroup, Inc.QOC 8.9ALCAlcon Inc.QOC 2.7MMSIMerit Medical Systems, Inc.QOC 8.7PDEXPro-Dex, Inc.QOC 7.8KRMDKORU Medical Systems, Inc.QOC 6.5NYXHNyxoah SAQOC 5.6

Read investment analysis: ISRG · LMAT · NNNN · ATR · ALC · MMSI · PDEX · KRMD · NYXH

Which Other Stocks Have a Similar Quality Score to RMD?

7 companies across all industries closest to RMD’s Quality of Company score of 9.4/10.

BUKSButler National CorporationQOC 9.4ONTOOnto Innovation Inc.QOC 9.4BLBDBlue Bird CorporationQOC 9.4EMEEMCOR Group, Inc.QOC 9.4NYTThe New York Times CompanyQOC 9.4TTTrane Technologies plcQOC 9.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BUKS · ONTO · BLBD · EME · NYT · TT · NVDA

Where Does RMD Sit in CirclFi's Medical Instruments & Supplies Rankings?

RMD is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About ResMed Inc.’s Valuation?

What is ResMed Inc.'s intrinsic value in 2026?

CirclFi puts ResMed Inc. (RMD)'s intrinsic value at $217.59 — the median of 11 independent model estimates as of 2026-08-27, ranging from $97.59 to $487.64. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $303.45 on its own. The Quality of Company score is 9.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RMD overvalued or undervalued right now?

At $235.76, 4 of 11 active models suggest RMD may be undervalued, while 7 indicate potential overvaluation. The median of all 11 fair value estimates is $217.59, within 7.7% of the current price of $235.76 — a consensus view that RMD is fairly valued. The assessment depends on which methodology best fits ResMed Inc.'s business model in Medical Instruments & Supplies.

What does a Quality of Company score of 9.4 mean for RMD?

ResMed Inc.'s QOC of 9.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on RMD?

CirclFi analyzes RMD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on RMD?

Of the 11 models currently active on RMD, Regime Cross-Sectional is the most bullish at $487.64 per share, and EROIC Spread is the most bearish at $97.59. CirclFi's published fair value for RMD is the median of that range, $217.59, not either extreme. The gap between the two ends equals 179% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is RMD a value trap in 2026?

ResMed Inc.'s Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, ResMed Inc. (RMD) has a median fair value of $217.59 — within 7.7% of the current price of $235.76 — as of 2026-08-27.” Source: circlfi.com/stock/RMD/ · Methodology
Primary sources for this RMD valuation
  • Financial statements: ResMed Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000943819) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for RMD as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on RMD.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for RMD Unlock All 11 — $39/mo